Freeman Chris reported option exercise involving 24,406 shares of Guardant Health, Inc. at $32.86 for $802k on May 22, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Commercial Officer
Chief Commercial Officer
Filed May 26, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$801,981.16Shares × reported price
Shares traded
24,406Common Stock
Price per share
$32.86Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
84,440Direct
Trade date
May 22, 2026Option exercise
Filed
May 26, 2026, 5:38 PM ET4-day reporting delay
Accession
0001871615-26-000010Code M · Transaction 385895
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 22, 2026Sell24,406$118.67−$2,896,360.08Trade 385896
May 22, 2026Option exercise24,406$0.00$0Trade 385897
3 transaction rows in this filing. Joint filers share the same rows.

GH price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GH · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −25%1w ago −21%1d ago −1.5%
Returns since7d +8.6%30d +19%90d +36%180d1y

Footnotes in full

F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.55 to $118.97. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F2: This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 9, 2024 and the remaining 67% of the shares subject to award vests each month during the two-year period thereafter.